BEAM BEAM THERAPEUTICS INC Business Restructuring 8-K Filing 2023 - Costs Associated with Exit or Disposal Activities Beam Therapeutics Inc. approved a portfolio prioritization and strategic restructuring, reducing its workforce by 20% and incurring one-time costs of $6.6 million in Q4 2023.Get access to all SEC 8-K filings of the BEAM THERAPEUTICS INC